Transcatheter Heart Valve Replacement - Market Insights, Competitive Landscape, and Market Forecast - 2030

Transcatheter Heart Valve Replacement Market by Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Replacement, and Transcatheter Pulmonary Valve Replacement), Application (Aortic Valve Stenosis, Aortic Valve Regurgitation, Mitral Valve Stenosis, Mitral Valve Regurgitation, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the growing prevalence of cardiovascular disorders and increasing product developmental activities worldwide

The transcatheter heart valve replacement market is estimated to grow at a CAGR of 13.75% during the forecast period from 2024 to 2030. The transcatheter heart valve replacement market is expanding rapidly due to the growing prevalence of cardiovascular disorders including circulatory diseases, various heart valve diseases, increasing product developmental activities such as regulatory clearances, rising sedentary lifestyle & lifestyle-associated disorders, increasing preference for minimally invasive surgeries that are expected to escalate the overall growth of the transcatheter heart valve replacement market during the forecast period from 2024 to 2030.

Transcatheter Heart Valve Replacement Market Dynamics:

According to the British Heart Foundation (BHF), it was reported in 2024, that around 640 million people in 2022 were living with heart and circulatory diseases across the world owing to changing lifestyles, aging, and a growing population.

As per data from the World Health Organization (WHO) 2020, the prevalence of calcific aortic valve stenosis was 9 million across the world. Thus, the increasing prevalence of cardiovascular diseases including circulatory diseases and various heart valve diseases will increase the demand for transcatheter heart valve replacement.

The increasing patient preference for minimally invasive surgeries is also likely to bode well for the market growth during the forecast period. Transcatheter heart valve replacement offer advantages over conventional surgeries owing to their minimally invasive approach, such as shorter recovery time, less post-operational pain, less stay at the hospital, fewer wound complications, and better wound prosthesis.

Additionally, in February 2024, Edwards Lifesciences Corporation announced launch of the Sapien 3 Ultra Resilia valve in Europe.

Therefore, the factors stated above collectively will drive the overall transcatheter heart valve replacement market growth.

However, presence of alternative treatment in the market, stringent regulatory approval process, among others may prove to be challenging factors for transcatheter heart valve replacement market growth.

Transcatheter Heart Valve Replacement Market Segment Analysis:

Transcatheter Heart Valve Replacement Market by Product (Transcatheter Aortic Valve Replacement, Transcatheter Mitral Valve Replacement, and Transcatheter Pulmonary Valve Replacement), Application (Aortic Valve Stenosis, Aortic Valve Regurgitation, Mitral Valve Stenosis, Mitral Valve Regurgitation, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the transcatheter heart valve replacement market, the transcatheter aortic valve replacement (TAVR) category is expected to have a significant revenue share in the year 2023. This is due to the increasing cases of aortic stenosis disorder as TAVR is the first-line surgical procedure performed for aortic stenosis. Further, the availability of technologically advanced devices in the market, and rising device launches and approvals will also affect the market positively.

The primary feature of this technique is its minimally invasive nature, as it involves accessing the aorta through the femoral artery in the groin, which typically results in a smaller incision and less surgical trauma. This approach leads to significant benefits, including a shorter recovery time.

Additionally, advancements in imaging and device technology have improved the precision of valve placement during the procedure, leading to better overall results. The transfemoral approach is also beneficial for patients with favorable femoral artery anatomy, as it allows for straightforward access without the need for complex surgical interventions.

Therefore the widespread uses and various features of transcatheter aortic valve replacement enhance performance and usability, solidifying the significant impact on the growth of the overall transcatheter heart valve replacement market during the forecast period from 2024 to 2030.

North America is expected to dominate the overall transcatheter heart valve replacement market:

Among all the regions, North America is expected to dominate the transcatheter heart valve replacement market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of myocardial infarction, heart valve diseases, and their associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the transcatheter heart valve replacement market in the North America region during the forecast period from 2024 to 2030.

Disease Control and Prevention (CDC) (2024), it was stated that 805,000 people in the US have a myocardial infarction (heart attack) every year on average. Furthermore, as per the same source, it was stated that heart disease is an umbrella term that encompasses numerous indications. Some of the key risk factors associated with heart disease are high blood cholesterol, high blood pressure, and smoking. The source further mentioned that about half of Americans (47%) have at least one of these three risk factors.

According to the Canadian Cardiovascular Society (2022), it was reported that in 2022, 2.5% of the population had heart valve diseases, which is increasing significantly after the age of 65, reaching up to 13% after the age of 75. It was also estimated by the same source that in 2040, Canada will have an estimated 1.5 million people over 65 years with heart valve disease.

Since cardiovascular disorders are rising in the region among middle-aged individuals, the demand for more effective treatment options is increasing significantly. This trend is fueling investment in innovative technologies and expanding the market for transcatheter heart valve replacement.

Rising product developmental activities by regulatory bodies and key players in the region will further boost the market for transcatheter heart valve replacement. For example, in September 2021, Abbott announced that the U.S Food and Drug Administration approved the company's Portico(TM) with FlexNav(TM) transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the North American transcatheter heart valve replacement market.

Transcatheter Heart Valve Replacement Market key players:

Some of the key market players operating in the transcatheter heart valve replacement market include Medtronic, Boston Scientific Corporation, Bracco SpA, Edward Lifesciences, Meril Lifesciences, JenaValve Technologies Inc., Venus Medtech (Hangzhou) Inc., Abbott, Bluesail Medical Co., Ltd., Braile Biomedica, CryoLife, Inc., SMT, Peijia Medical Limited, P+F Products + Features GmbH, Livanova Plc, and others.

Recent Developmental Activities in the Transcatheter Heart Valve Replacement Market:

• In August 2024, Boston Scientific Corporation announced that it secured CE mark for the ACURATE Prime(TM) Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology.
• In January 2022, Medtronic announced that the National Medical Products Administration (NMPA) approved the CoreValve Evolut PRO TAVR system for the treatment of severe aortic stenosis (AS) for symptomatic patients in China who are at high or extreme risk for open heart surgery.

Key Takeaways from the Transcatheter Heart Valve Replacement Market Report Study

• Market size analysis for current transcatheter heart valve replacement market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the transcatheter heart valve replacement market
• Various opportunities available for the other competitors in the Transcatheter Heart Valve Replacement market space
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current transcatheter heart valve replacement market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for transcatheter heart valve replacement market growth in the coming future?

Target Audience who can be benefited from this Transcatheter Heart Valve Replacement Market Report Study

• Transcatheter heart valve replacement product providers
• Research organizations and consulting companies
• Transcatheter heart valve replacement-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in transcatheter heart valve replacement
• Various end-users who want to know more about the transcatheter heart valve replacement market and the latest technological developments in the transcatheter heart valve replacement market

Frequently Asked Questions for the Transcatheter Heart Valve Replacement Market:

1. What are transcatheter heart valve replacement?

• The transcatheter heart valve replacement is a procedure with a less invasive approach that helps replace the heart valve with a prosthetic valve to treat severe aortic stenosis and mitral regurgitation. It is an effective alternative to cumbersome open heart surgery, especially for high-risk patients.

2. What is the market for transcatheter heart valve replacement?

• The transcatheter heart valve replacement market is estimated to grow at a CAGR of 13.75% during the forecast period from 2024 to 2030.

3. What are the drivers for the transcatheter heart valve replacement market?

• The transcatheter heart valve replacement market is expanding rapidly due to the growing prevalence of cardiovascular disorders including circulatory diseases, various heart valve diseases, increasing product developmental activities such as regulatory clearances, rising sedentary lifestyle & lifestyle-associated disorders, increasing preference for minimally invasive surgeries that are expected to escalate the overall growth of the transcatheter heart valve replacement market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the transcatheter heart valve replacement market?

• Some of the key market players operating in transcatheter heart valve replacement include Medtronic, Boston Scientific Corporation, Bracco SpA, Edward Lifesciences, Meril Lifesciences, JenaValve Technologies Inc., Venus Medtech (Hangzhou) Inc., Abbott, Bluesail Medical Co., Ltd., Braile Biomedica, CryoLife, Inc., SMT, Peijia Medical Limited, P+F Products + Features GmbH, Livanova Plc, and others.

5. Which region has the highest share in the transcatheter heart valve replacement market?

• Among all the regions, North America is expected to dominate the transcatheter heart valve replacement market in the year 2023 and is expected to do the same during the forecast period. This can be attributed to several factors including the high instances of myocardial infarction, heart valve diseases, and its associated risk factors, combined with significant advancements in product development & regulatory approvals, the presence of market key players, and the availability of well-established advanced healthcare infrastructure that are acting as key factors contributing to the growth of the transcatheter heart valve replacement market in the North America region during the forecast period from 2024 to 2030.